Document Detail


Preference for palatable food is reduced by the gamma-hydroxybutyrate analogue GET73, in rats.
MedLine Citation:
PMID:  17240159     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Palatability and variety of foods are major reasons for "hedonic" eating, and hence for overeating and obesity. Palatable food and drugs of abuse share a common reward mechanism, and compounds that block the reinforcing effect of drugs of abuse preferentially suppress the intake of palatable foods. This research was aimed at studying the influence of the gamma-hydroxybutyrate analogue N-(4-trifluoromethylbenzyl)-4-methoxybutanamide (GET73) - that inhibits alcohol consumption - on consumption and reinforcing effect of palatable food. Adult male rats were used. For place preference conditioning, sweetened corn flakes were used as the reinforcer, and GET73 (50, 100 and 200mgkg(-1)) or vehicle were orally (p.o.) administered either 30min before each training session and the test session, or only before the test session. To study the influence on consumption, GET73 was given p.o. at the same doses once daily for 12 days to rats given free access to both palatable and varied food (cafeteria diet) or to standard chow. Both acquisition and expression of palatable food-induced conditioned place preference were inhibited by GET73, either administered throughout the conditioning period or only before the test session. GET73 reduced also the consumption of cafeteria food, while that of standard chow was increased. At these doses, GET73 had no detrimental effect on open-field behaviour. GET73 seems to specifically attenuate the gratification produced by varied and palatable food, without affecting the consumption of not particularly palatable chow. Since, overweight and obesity are mostly due to the overeating of palatable and varied foods, drugs like GET73 could represent a somewhat ideal and rational approach to obesity treatment.
Authors:
Alessandra Ottani; Sheila Leone; Francisca Belen Garcia Vergara; Raffaella Tacchi; Antonella Loche; Alfio Bertolini
Related Documents :
12914999 - Reinforcement context and resistance to change.
4752089 - Drugs and punished responding. ii. d-amphetamine-induced increases in punished responding.
11457319 - Aptamer-based folding fluorescent sensor for cocaine.
17707949 - Deconstructing the vanilla milkshake: the dominant effect of sucrose on self-administra...
22763449 - The diet of australopithecus sediba.
16811999 - Demand for food on fixed-ratio schedules as a function of the quality of concurrently a...
17876909 - A global perspective on energy: health effects and injustices.
9176829 - Dietary, anthropometric, hematological and biochemical assessment of the nutritional st...
6533009 - N-nitrosoproline excretion in urine, faeces and milk from cows in relation to feed comp...
Publication Detail:
Type:  Journal Article     Date:  2006-12-19
Journal Detail:
Title:  Pharmacological research : the official journal of the Italian Pharmacological Society     Volume:  55     ISSN:  1043-6618     ISO Abbreviation:  Pharmacol. Res.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-09     Completed Date:  2007-08-29     Revised Date:  2014-03-25    
Medline Journal Info:
Nlm Unique ID:  8907422     Medline TA:  Pharmacol Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  271-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anilides / pharmacology*
Animals
Anti-Obesity Agents / pharmacology*
Behavior, Animal / drug effects*
Conditioning (Psychology) / drug effects
Dose-Response Relationship, Drug
Food Preferences / drug effects*
Male
Motor Activity / drug effects
Rats
Rats, Wistar
Reinforcement (Psychology)*
Reinforcement Schedule
Reward
Taste*
Chemical
Reg. No./Substance:
0/Anilides; 0/Anti-Obesity Agents; 0/N-(4-trifluoromethylbenzyl)-4-methoxybutanamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  FcgammaR: The key to optimize therapeutic antibodies?
Next Document:  Metal-complex formation in continuous-flow ligand-exchange reactors studied by electrospray mass spe...